U.S. flag

An official website of the United States government

NC_000012.12:g.(?_110910819)_(110911175_?)del AND Hypertrophic cardiomyopathy 10

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Dec 27, 2016
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000469216.1

Allele description

NC_000012.12:g.(?_110910819)_(110911175_?)del

Gene:
MYL2:myosin light chain 2 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
12q24.11
Genomic location:
Preferred name:
NC_000012.12:g.(?_110910819)_(110911175_?)del
HGVS:
  • NC_000012.12:g.(?_110910819)_(110911175_?)del
  • NC_000012.11:g.(?_111348623)_(111348979_?)del

Condition(s)

Name:
Hypertrophic cardiomyopathy 10
Synonyms:
CARDIOMYOPATHY, HYPERTROPHIC, MID-LEFT VENTRICULAR CHAMBER TYPE, 2; Familial hypertrophic cardiomyopathy 10; MYL2-Related Familial Hypertrophic Cardiomyopathy
Identifiers:
MONDO: MONDO:0012112; MedGen: C1834460; OMIM: 608758

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000563919Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Dec 27, 2016)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Invitae, SCV000563919.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This variant is a gross deletion of the genomic region encompassing exon 7 of the MYL2 gene. The 5' boundary is likely confined to intron 6. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. This variant results in the deletion of the EF-hand calcium binding domain 3 (PMID: 4942892, 678511, 26074085 ). This domain contains amino acid residues required for protein function that have been involved in pathogenic variants, such as p.Asp166Val (PMID: 12707239, 23727233, 18987303). Furthermore, an intron 6 acceptor splice site variant (c403-1G>C) causing a frameshift and replacement of the Exon 7 coded amino acids by 19 unrelated ones has been reported in the homozygous state in several individuals affected with infantile type I muscle fibre disease and cardiomyopathy, and has been shown to have a deep impact on protein function (PMID: 23365102, 27378946). This indicates that MYL2 exon 7 codes for a functionally important region of the protein. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Mar 26, 2023